Use of aspirin in reduction of mortality of COVID-19 patients: A meta-analysis.
Int J Clin Pract
; 75(11): e14515, 2021 Nov.
Article
in English
| MEDLINE | ID: covidwho-1341257
ABSTRACT
COVID-19 infection, affecting every one of us from the last year. Emerging reports have indicated thromboembolism in serious cases of COVID-19. The aspirin is useful to reduce mortality of serious patients with acute respiratory distress syndrome without COVID-19. Thus, we have conducted a metanalysis to find out the role of aspirin in the mortality of COVID-19 patients using RevMan 5. A total of 10 studies containing 56 696 COVID-19 patients were found appropriate for quantitative analysis. The quality of articles was assessed using Newcastle-Ottawa scale. The fixed-effect model was used to calculate the odds ratio with 95% confidence interval (CI). The odd ratio was found to be 0.70 [0.63, 0.77] which indicates a lesser likelihood of having death in COVID-19 patients in aspirin group as compared with non-aspirin group. However, no effect 0.00 [-0.04, 0.04] was observed after the exclusion of outliers. Thus, further clinical evidence is required to make valid conclusion.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Respiratory Distress Syndrome
/
COVID-19
Type of study:
Prognostic study
/
Reviews
Limits:
Humans
Language:
English
Journal:
Int J Clin Pract
Journal subject:
Medicine
Year:
2021
Document Type:
Article
Affiliation country:
Ijcp.14515
Similar
MEDLINE
...
LILACS
LIS